Leap Therapeutics Acquires Flame Biosciences
01/17/23, 1:10 PM
Location
cambidge
new york
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flame Biosciences, Inc., a privately-held biotechnology company, today announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022.
Company Info
Location
Cambidge, Massachusetts, United States
Company info
Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.
For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.